MannKind Corp (MNKD) Q1 2024 Earnings Call Transcript Highlights: A Quarter of Robust Growth ...
MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments
MannKind Price Target Maintained With a $6.50/Share by Cantor Fitzgerald
MannKind Price Target Maintained With a $6.50/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target
Cantor Fitzgerald analyst Olivia Brayer reiterates MannKind with a Overweight and maintains $6.5 price target.
MannKind Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 50.99% Cantor Fitzgerald → $6.5 Reiterates Overweight → Overweight 03/15/2024 50.99% Cantor Fit
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)
Earnings Call Summary | MannKind(MNKD.US) Q1 2024 Earnings Conference
The following is a summary of the MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript:Financial Performance:MannKind Corporation reported Q1 revenue growth of over 250% in the last eight quar
MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript
MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind Corp. Q1 Earnings Summary
MannKind Q1 2024 Adj EPS $0.05 Beats $0.03 Estimate, Sales $66.263M Beat $60.490M Estimate
MannKind (NASDAQ:MNKD) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.03 by 66.67 percent. This is a 350 percent increase over losses of $(0.02) per sha
Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05
04:19 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, Vs. Street Est of $60.6M
04:19 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M
MannKind | 10-Q: Quarterly report
MannKind 1Q EPS 4c >MNKD
MannKind 1Q EPS 4c >MNKD
MannKind 1Q Net $10.6M >MNKD
MannKind 1Q Net $10.6M >MNKD
MannKind 1Q Rev $66.3M >MNKD
MannKind 1Q Rev $66.3M >MNKD
Press Release: MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update Conference Call to Begin Today at 5:00 p.m. (ET) -- 1Q 2024 Total revenues of $66M; +63% vs
MannKind Q1 24 Earnings Conference Call At 5:00 PM ET
No Data